Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
Abstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pem...
Автори: | Tsutomu Hirano, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Satoshi Goto, Masako Tomoyasu, Takeshi Yamamoto, Makoto Ohara, Michishige Terasaki, Hideki Kushima, Yasuki Ito, Sho‐ichi Yamagishi, Yusaku Mori |
---|---|
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Wiley
2023-12-01
|
Серія: | Journal of Diabetes Investigation |
Предмети: | |
Онлайн доступ: | https://doi.org/10.1111/jdi.14076 |
Схожі ресурси
Схожі ресурси
-
Case series showing the safety and changes in lipid profiles of hemodialysis patients with hypertriglyceridemia after pemafibrate administration
за авторством: Rino Okada, та інші
Опубліковано: (2024-12-01) -
Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
за авторством: Junko Oya, та інші
Опубліковано: (2023-11-01) -
Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
за авторством: Masahiro Kikuchi, та інші
Опубліковано: (2024-09-01) -
Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
за авторством: Hiroshi Nomoto, та інші
Опубліковано: (2023-06-01) -
Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data
за авторством: Aki Okamoto, та інші
Опубліковано: (2025-02-01)